Jin-Long Chen Biography and Net Worth

Dr. Chen is NGM’s Founder and has served as a member of our board of directors and as Chief Scientific Officer since January 2008. He was also NGM’s President until November 2014. Previously, Dr. Chen held various positions at Amgen, most recently as its Vice President, Metabolic Disorders, with responsibility for leading the company’s global research efforts in small molecule and biologic drug discovery for the treatment of human diseases affecting metabolism, bone, mineral balance and muscle. Prior to joining Amgen, he served as Vice President of Biology at Tularik where he guided drug discovery research in oncology, inflammation and metabolic disease. Dr. Chen’s pioneering work on a broad array of targets at both Amgen and Tularik not only opened up opportunities to study new aspects of biology and physiology across disease areas, but also led to contributions of multiple drug candidates to the development pipelines of these organizations, including RepathaTM (evolocumab), a novel anti-PCSK9 antibody that lowers low-density lipoprotein cholesterol.

Dr. Chen received a B.S. in Nutrition and Food Science from Fu-Jen Catholic University, and a M.S. in biochemistry from National Taiwan University. He completed his graduate training at the University of California, Berkeley in 1994, receiving a Ph.D. for his research on the mechanisms of transcription carried out in the laboratory of Prof. Robert Tjian.

What is Jin-Long Chen's net worth?: The estimated net worth of Jin-Long Chen is at least $1.40 million as of January 17th, 2023. Dr. Chen owns 908,893 shares of NGM Biopharmaceuticals stock worth more than $1,399,695 as of April 26th. This net worth estimate does not reflect any other investments that Dr. Chen may own. Learn More about Jin-Long Chen's net worth.
How do I contact Jin-Long Chen?: The corporate mailing address for Dr. Chen and other NGM Biopharmaceuticals executives is 333 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. NGM Biopharmaceuticals can also be reached via phone at (650) 243-5555 and via email at [email protected]. Learn More on Jin-Long Chen's contact information.
Has Jin-Long Chen been buying or selling shares of NGM Biopharmaceuticals?: Jin-Long Chen has not been actively trading shares of NGM Biopharmaceuticals during the past quarter. Most recently, Jin-Long Chen sold 85,082 shares of the business's stock in a transaction on Tuesday, January 17th. The shares were sold at an average price of $5.15, for a transaction totalling $438,172.30. Following the completion of the sale, the insider now directly owns 908,893 shares of the company's stock, valued at $4,680,798.95. Learn More on Jin-Long Chen's trading history.
Who are NGM Biopharmaceuticals' active insiders?: NGM Biopharmaceuticals' insider roster includes Jin-Long Chen (Insider), Hsiao Lieu (SVP), and David Woodhouse (CEO). Learn More on NGM Biopharmaceuticals' active insiders.

Jin-Long Chen Insider Trading History at NGM Biopharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/17/2023	Sell	85,082	$5.15	$438,172.30	908,893
12/6/2021	Sell	15,000	$18.21	$273,150.00
11/15/2021	Sell	30,000	$19.73	$591,900.00
10/11/2021	Sell	15,000	$20.41	$306,150.00
9/13/2021	Sell	15,000	$26.03	$390,450.00
8/9/2021	Sell	15,000	$24.46	$366,900.00
4/12/2021	Sell	25,000	$24.65	$616,250.00	945,005
3/1/2021	Sell	25,000	$26.66	$666,500.00	970,005
1/4/2021	Sell	25,000	$29.28	$732,000.00	870,375
12/14/2020	Sell	25,000	$28.01	$700,250.00	908,879
10/12/2020	Sell	25,000	$17.02	$425,500.00	945,005
9/1/2020	Sell	25,000	$17.83	$445,750.00	977,618
7/1/2020	Sell	25,000	$18.91	$472,750.00	1,027,268
6/15/2020	Sell	25,000	$21.65	$541,250.00
1/9/2020	Sell	18,641	$17.95	$334,605.95	1,012,783
1/7/2020	Sell	16,090	$18.20	$292,838.00	1,012,783
11/4/2019	Sell	50,765	$12.67	$643,192.55

Jin-Long Chen Buying and Selling Activity at NGM Biopharmaceuticals

NGM Biopharmaceuticals Company Overview

NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company develops NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced metastatic solid tumors; and Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of primary sclerosing cholangitis and non-alcoholic steatohepatitis. It also develops NGM120, an GFRAL antagonist antibody, which is in Phase II clinical trial to treat hyperemesis gravidarum; NGM831 and NGM438 which is in phase I/II clinical trial for the treatment of advanced solid tumors; and NGM621, an monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck to focus primarily on the identification, research and development of collaboration compounds directed to targets in the fields of ophthalmology and cardiovascular or metabolic, or CVM, disease, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.

Today's Range

Now: $1.54

$1.54

$1.57

50 Day Range

MA: $1.57

$1.52

$1.92

2 Week Range

Now: $1.54

$0.60

$4.69

Volume

2,390,800 shs

Average Volume

1,467,160 shs

Market Capitalization

$128.53 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.27

These AI trades triggered this morning (545% return)

From Prosper Trading Academy | Ad

If you think a market crash is possible in 2024, I don't know why you're not using this yet.

Click Here To Get Your Free Copy